O EV/EBITDA de Zynex Inc é 18.13
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.